证券代码：002550 证券简称：千红制药 公告编号：2024-024 常州千红生化制药股份有限公司 关于继续为控股子公司提供贷款担保的公告 一、担保情况概述 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 常州千红生化制药股份有限公司（以下简称："公司"或"本公司"）第六届 董事会第三次会议审议通过了《公司继续为控股子公司提供贷款担保的议案》， 现将担保事项公告如下： 一、担保情况概述 本公司控股子公司江苏众红生物工程创药研究院有限公司（以下简称："江 苏众红"）因研发投入的持续增加及日常运营的需要，需要向银行申请流动资金 贷款授信。 本公司为江苏众红的综合贷款授信继续提供担保，担保金额累计不超过 2000 万元人民币。 上述担保期限均为：自其担保合同生效之日起壹年以内。本次担保事项在董 事会审议范围之内，无需提交股东大会审议。 二、被担保人基本情况 注册地址：常州市新北区云河路 518 号 法定代表人：王耀方 注册资本：980 万美元 主营业务为：生物医药产品与中间体、生物医药试剂、体外诊断试剂、营养 保健品、再生医学材料与制品、功能性生物材料、生物化学产 ...

常州千红生化制药股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要 求（以下简称企业内部控制规范体系），结合本公司（以下简称公司）内部控制 制度和评价办法，在内部控制日常监督和专项监督的基础上，董事会对公司在 2023年度（内部控制评价报告基准日为2023年12月31日）的内部控制有效性进行 了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。经理室负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及 相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控制存 在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的变化 可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低，根据内部 控制评 ...

Financial Performance - The company's operating revenue for 2023 was approximately ¥1.81 billion, a decrease of 21.24% compared to ¥2.30 billion in 2022[22]. - The net profit attributable to shareholders for 2023 was approximately ¥181.86 million, down 43.77% from ¥323.41 million in 2022[22]. - The basic earnings per share for 2023 was ¥0.14, a decline of 44.00% from ¥0.25 in 2022[23]. - The total assets at the end of 2023 were approximately ¥2.77 billion, a decrease of 1.42% from ¥2.81 billion at the end of 2022[23]. - The net cash flow from operating activities for 2023 was approximately ¥533.33 million, a significant increase of 846.19% compared to a negative cash flow of ¥71.47 million in 2022[22]. - The company reported a quarterly revenue of ¥608.22 million in Q1 2023, which decreased to ¥348.33 million in Q4 2023[27]. - The company experienced a net loss of approximately ¥15.99 million in Q4 2023, contrasting with a net profit of ¥85.95 million in Q1 2023[27]. - The company reported non-operating income of approximately ¥38.38 million in 2023, down from ¥65.21 million in 2022[30]. - In 2023, the company's revenue was 1.814 billion yuan, a decrease of 21.24% compared to the previous year[48]. - The net profit for 2023 was 182 million yuan, down 43.77% year-on-year[48]. Dividend Distribution - The company plans to distribute a cash dividend of 1.2 CNY per 10 shares to all shareholders, based on a total of 1,249,800,000 shares[4]. - The company distributed a cash dividend of RMB 1.2 per 10 shares, totaling RMB 149,976,000, based on a share base of 1,249,800,000 shares[141]. - The total distributable profit at the end of the reporting period was RMB 873,978,695.92, with the cash dividend representing 100% of the profit distribution[142]. - The company has a mature development stage and aims for a minimum of 80% cash dividend distribution in profit allocation[141]. Market Position and Strategy - The biopharmaceutical industry in which the company operates is experiencing rapid growth, making China the second-largest pharmaceutical market globally after the United States[34]. - The company is a leading enterprise in the domestic biopharmaceutical industry, focusing on innovative drugs and maintaining a leading market share in heparin sodium injection and sealing liquid[36]. - The company has successfully captured market opportunities from national centralized procurement policies, leading to significant growth in the revenue of the Enoxaparin series products[36]. - The company is actively exploring new strategic collaborations, including an OTC strategic partnership with Bayer Pharmaceuticals, to enhance brand recognition and market competitiveness[36]. - The company is positioned to benefit from national policies aimed at encouraging innovation and supporting the development of new drugs, as outlined in the "High-Quality Development Action Plan for the Pharmaceutical Industry (2023-2025)"[39]. - The company has established a professional international marketing team and a network in countries like the USA, Germany, and Japan[44]. - The company is focusing on strategic key customers and new potential markets under the Belt and Road Initiative[48]. Research and Development - The company has established two joint research institutes and an offshore drug research and development center, enhancing its innovation capabilities[37]. - The company has three innovative drugs entering Phase II clinical trials, with one additional innovative drug receiving clinical trial approval, strengthening its core competitiveness[37]. - In 2023, the company applied for 21 invention patents in biopharmaceutical innovation, with one new drug entering phase II clinical trials and three more set to enter soon, enhancing its core competitiveness[49]. - The company is advancing multiple new drug projects, including QHRD107 and QHRD110, which are in various stages of clinical trials aimed at enhancing the product pipeline and core competitiveness[75]. - The company aims to accelerate the R&D process for five new drugs, particularly focusing on the Phase II clinical trial of QHRD107, with the goal of achieving early results in 2024[95]. - The company has allocated a budget of 50 million for R&D in the next fiscal year to support innovation initiatives[120]. Operational Efficiency - The gross profit margin for the biopharmaceutical sector improved to 43.07%, up 4.60% from the previous year[62]. - The company reported a significant increase in other business revenue by 358.99%, reaching ¥5,172,502.21[61]. - The total operating cost decreased by 27.28% to ¥1,028,402,11, with raw materials constituting 94.18% of the total costs[66]. - The company emphasized the importance of optimizing product structure and improving management capabilities to address existing challenges[58]. - The company has established a comprehensive production technology quality management system, with nearly 80,000 square meters of facilities meeting GMP standards, contributing to its competitive edge in both domestic and international markets[50][51]. Risk Management - The company has detailed its future risks and countermeasures in the report, emphasizing the importance of investor awareness regarding investment risks[4]. - The company faces significant risks from drug procurement policies leading to potential price declines in product sales[98]. - Increased investment in new drug research and development poses risks to profit margins due to the lengthy and costly nature of the process[98]. - Rising operational costs are anticipated due to fluctuations in raw material prices, increased labor costs, and higher R&D expenses[99]. - The tightening of environmental policies adds uncertainty and risk to the company's operations[98]. - The company plans to implement a robust risk management system to ensure stable operations across key areas, including sales expense control and strategic investment project oversight[96]. Corporate Governance - The company strictly adheres to corporate governance regulations, ensuring compliance with laws and enhancing operational standards[105]. - The internal audit department is in place to oversee economic operations and compliance with internal controls[107]. - The company has established a clear organizational structure, ensuring independence from controlling shareholders in decision-making processes[111]. - The board of directors held four meetings in 2023, with significant resolutions announced on January 6, April 13, July 21, and October 24, demonstrating active governance and decision-making processes[127]. - The audit committee held 3 meetings, discussing key financial reports and internal audits for 2022[131]. - The company is committed to enhancing its internal control systems and governance practices in line with regulatory requirements[130]. Environmental Responsibility - The company has complied with environmental protection laws and standards, ensuring responsible waste management and emissions control[154]. - The company has established a wastewater treatment station at the Changjiang Road plant, which utilizes a combination of physical and biological processes to meet discharge standards before releasing effluent to the local sewage treatment plant[157]. - The company reported that the concentration of COD in wastewater from the Changjiang Road plant was 45.84 mg/L, significantly below the regulatory limit of 500 mg/L[156]. - The company has implemented an automatic monitoring system for wastewater discharge, including online detection of COD, total nitrogen, pH, and flow rate[158]. - The company has invested in environmental protection measures and has complied with the requirements for environmental protection tax payments[158]. - The company incurred environmental expenses of approximately RMB 4.5817 million during the reporting period, including investments in environmental facilities and pollutant treatment[159]. Workforce and Talent Management - The company has a strong talent pool, with nearly 20 PhDs and over 80 master's degree holders, ensuring a solid foundation for future strategic development[51]. - The company has no retired employees and maintains a workforce with a significant number of highly educated staff, including 111 with master's degrees or higher[136]. - The company emphasizes employee training, offering diverse programs to enhance skills and knowledge, including management training for senior staff[138]. - The company has established a competitive salary system based on performance and market conditions, ensuring fairness and efficiency in compensation[137]. Subsidiaries and Investments - The company has established a new subsidiary, Henan Qianmu Biopharmaceutical Co., Ltd., with a registered capital of ¥100 million, focusing on drug production and related services[70]. - The company has expanded its investment activities through the establishment of Changzhou Qianhong Biotechnology Co., Ltd., with a registered capital of ¥21 million[70]. - The company and Muyuan Food Co., Ltd. jointly invested in establishing Henan Qianmu Biopharmaceutical Co., Ltd. with a registered capital of CNY 100 million, where the company holds a 51% stake[193]. Shareholding and Management Stability - The management team remains stable with no significant changes in shareholding among key executives[114]. - The overall stability in shareholding among executives suggests confidence in the company's strategic direction[114]. - The company reported a total shareholding of 255,400 shares for Wang Yao, with no changes during the period[113]. - The company has appointed new independent directors, including Gao Yu and Ren Xiang, both holding 0 shares[114].

常州千红生化制药股份有限公司 利润分配政策及未来三年股东回报规划（2024 年-2026 年） 为进一步完善和健全常州千红生化制药股份有限公司（以下简称"公司"） 科学、持续、稳定的分红决策和监督机制，保持利润分配政策的连续性和稳定性， 积极回报股东，引导股东树立长期投资和理性投资的理念，根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《关于进一步落实上市公司现金分红有关事 项的通知》、《上市公司监管指引第 3 号——上市公司现金分红》等相关法律、法 规、规范性文件以及《常州千红生化制药股份有限公司章程》（以下简称"《公 司章程》"）的相关规定，结合公司的实际情况，特制订以下公司利润分配政策 及未来三年股东回报规划（2024 年-2026 年）： 一、利润分配政策 公司实施利润分配应当遵循以下规定： （一）利润分配顺序 1．公司分配当年税后利润时，应当提取利润的百分之十列入公司法定公积 金。公司法定公积金累计额为公司注册资本的百分之五十以上的，可以不再提取； 2．公司的法定公积金不足以弥补以前年度亏损的，在依照前款规定提取法 定公积金之前，应当先用当年利润弥补亏损； 3．公司从税后利润中提取法定公积 ...

证券代码：002550 证券简称：千红制药 公告编号：2024-016 常州千红生化制药股份有限公司 关于第一期员工持股计划"千红制药 1 号" 存续期延期的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 常州千红生化制药股份有限公司（以下简称"本公司"或"公司"）于 2024 年 3 月 22 日召开了第六届董事会第二次会议，会议审议通过了《关于公司第一 期员工持股计划"千红制药 1 号"存续期延期的议案》，同意将公司第一期员工 持股计划"千红制药 1 号"的存续期延长 12 个月，即延长至 2025 年 3 月 31 日。现将相关情况公告如下： 一、员工持股计划的基本情况 公司于 2019 年 8 月 29 日分别召开了第四届董事会第十五次会议、第四届监 事会第十四次会议，于 2019 年 9 月 25 日召开了 2019 年第一次临时股东大会， 审议通过了《公司第一期员工持股计划（草案）及其摘要的议案》等相关议案， 具体内容详见公司于 2019 年 8 月 30 日、2019 年 9 月 26 日在巨潮资讯网 （www.cninfo.com.cn） ...

本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 常州千红生化制药股份有限公司（以下简称"公司）"于 2024 年 1 月 2 日 召开第五届董事会第十五次会议和第五届监事会第十四次会议，审议通过了《关 于回购公司股份方案的议案》，同意使用自有资金以集中竞价交易的方式回购公 司发行的人民币普通股（A 股）股票，本次回购的股份将用于后续实施员工持股 计划或股权激励计划，回购的资金总额不低于人民币 8500 万元（含）且不超过 人民币 17000 万元（含），回购价格上限 6.8 元/股。本次回购实施期限为自公司 董事会审议通过本次回购股份方案之日起不超过 12 个月。 截至 2024 年 3 月 22 日，公司通过回购专用证券账户以集中竞价交易方式已 累计回购股份 25,000,000 股，占公司目前总股本的 1.95%，最高成交价为 6.06 元 /股，最低成交价为 4.47 元/股，支付的回购总金额为 140,756,897 元（不含交易 费用），本次回购符合相关法律法规的要求，符合公司既定的回购方案。 公司于 2024 年 3 月 22 日召开第六届董事会第 ...

证券代码：002550 证券简称：千红制药 公告编号：2024-015 表决结果：9 票同意，0 票弃权，0 票反对，议案获得通过。 《关于第一期员工持股计划"千红制药 1 号"存续期延期的公告》详见巨潮 资讯网 www.cninfo.com.cn。 二、审议并通过了《关于完成公司回购方案的议案》 截至 2024 年 3 月 22 日，公司通过回购专用证券账户以集中竞价交易方式已 累计回购股份 25,000,000 股，符合公司既定的回购方案以及相关法律法规的要 求，在综合考虑回购股份数量已达既定目标以及回购股份后续的实施计划后，公 司决定提前完成回购股份事项。 常州千红生化制药股份有限公司 第六届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 常州千红生化制药股份有限公司（以下简称"本公司"或"公司"）第六届 董事会第二次会议通知于 2024 年 3 月 18 日通过邮件方式送达，会议于 2024 年 3 月 22 日在公司云河路厂区会议室召开，会议应参加董事 9 人，实参加 9 人。 会议由董事长王耀方先生召集并主持。本次会议的通 ...

Investment Rating - The report gives a "Buy" rating for Qianhong Pharmaceutical (002550) [9][11]. Core Viewpoints - The company is expected to benefit from a rebound in heparin raw material prices and has established a partnership with Muyuan to enhance its high-end heparin production capabilities [6]. - The innovative drug development is progressing well, with QHRD107 (a CDK9 inhibitor) leading in clinical trials for AML, and QHRD110 (a CDK4/6 inhibitor) showing promise in bridging trials in China [7]. - The company has a strong market position in protease products, with significant market share and ongoing collaborations to expand its OTC market presence [10]. Summary by Sections Company Overview - The company is a leader in the animal-derived enzyme and heparin sectors, with a comprehensive heparin industry chain and a focus on polysaccharides and protease drugs [33][58]. Financial Performance - Revenue grew from 1.322 billion in 2018 to 2.304 billion in 2022, with a CAGR of 14.90%. However, a decline of 11.09% was noted in the first three quarters of 2023 due to market conditions [71]. - The company’s gross margin decreased from 48.89% in 2018 to 38.59% in 2022, but showed recovery to 42.93% in the first three quarters of 2023 [72]. Heparin Industry Insights - Heparin raw material prices are expected to enter a new upward cycle in 2024, with the company positioned to benefit from this trend [6]. - The company has established a joint venture with Muyuan to create a modern production line for high-end heparin, expected to be operational by the end of 2024 [6]. Innovative Drug Development - QHRD107 is advancing in clinical trials for AML, with a favorable competitive landscape, while QHRD110 is targeting brain glioma indications [7]. - The company is also developing products for acute ischemic stroke and growth hormone deficiency, which could contribute to a second growth curve [7]. Market Position and Strategy - The company maintains a leading market share in its enzyme products, with a strong sales presence in hospitals and ongoing partnerships to enhance market reach [10]. - The company’s heparin sodium injection has seen rapid market share growth, and the recent successful bidding for heparin sodium injection in national procurement is expected to boost its market penetration [17].

关于回购公司股份进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 常州千红生化制药股份有限公司（以下简称"公司）"于 2024 年 1 月 2 日 召开第五届董事会第十五次会议和第五届监事会第十四次会议，审议通过了《关 于回购公司股份方案的议案》，同意使用自有资金以集中竞价交易的方式回购公 司发行的人民币普通股（A 股）股票，本次回购的股份将用于后续实施员工持股 计划或股权激励计划，回购的资金总额不低于人民币 8500 万元（含）且不超过 人民币 17000 万元（含），回购价格上限 6.8 元/股。本次回购实施期限为自公司 董事会审议通过本次回购股份方案之日起不超过 12 个月。 在回购期间，公司按照相关法律、法规就回购期间的进展情况进行了披露， 具体内容详见公司于 2024 年 1 月 17 日、2024 年 2 月 3 日在《证券时报》、《中 国证券报》和巨潮资讯网（www.cninfo.com.cn）披露的《关于回购股份比例达到 1%暨回购进展的公告》（公告编号：2024-009）、《关于回购公司股份进展的公告》 （2024-013）。 根据 ...

关于回购公司股份进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 常州千红生化制药股份有限公司（以下简称"公司）"于 2024 年 1 月 2 日 召开第五届董事会第十五次会议和第五届监事会第十四次会议，审议通过了《关 于回购公司股份方案的议案》，同意使用自有资金以集中竞价交易的方式回购公 司发行的人民币普通股（A 股）股票，本次回购的股份将用于后续实施员工持股 计划或股权激励计划，回购的资金总额不低于人民币 8500 万元（含）且不超过 人民币 17000 万元（含），回购价格上限 6.8 元/股。本次回购实施期限为自公司 董事会审议通过本次回购股份方案之日起不超过 12 个月。公司于 2024 年 1 月 17 日披露了《关于回购股份比例达到 1%暨回购进展的公告》，具体内容详见公 司在《证券时报》、《中国证券报》和巨潮资讯网（www.cninfo.com.cn）披露的相 关公告。 证券代码：002550 证券简称：千红制药 公告编号：2024-013 常州千红生化制药股份有限公司 根据《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》 ...